More support for testing CTC as a diagnostic tool in formulating treatment plans for mCSPC patients. From the MedPageToday interview article:
"Baseline circulating tumor cell (CTC) count was found to be significantly predictive of clinical outcome in a phase III trial of metastatic castration-sensitive prostate cancer (mCSPC) presented at the 2020 American Society of Clinical Oncology virtual scientific meeting."
"In this exclusive MedPage Today video, lead researcher Amir Goldkorn, MD, of the Keck School of Medicine and Norris Comprehensive Cancer Center at the University of Southern California, explains that the results suggest that CTC count could be used as a noninvasive biomarker to help guide treatment decisions."
Link to interview and transcript is here:
medpagetoday.com/meetingcov...
And Dr. Goldkorn's JCO Precision Oncology/ASCO research paper is here:
Abstract:
ascopubs.org/doi/pdf/10.120...
Full Report:
sci-hub.tw/10.1200/PO.19.00383
Be Safe & Stay Well - K9